Compounds > trovafloxacin
Page last updated: 2024-08-24

trovafloxacin and E coli Infections

trovafloxacin has been researched along with E coli Infections in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cimochowski, CR; Faiella, JA; Girard, AE; Girard, D; Gootz, TD1
Brown, P; Chuah, SK; Esfandiari, A; Gollapudi, S; Hanna, N; Malilay, C; Polzer, RJ; Reddy, U; Thadepalli, F; Thadepalli, H1
Barzilai, A; Diamantstein, L; Gruzman, G; Keller, N; Rubinovitch, B; Rubinstein, E; Yoseph, G1
Goessens, WH; Gyssens, IC; Mouton, JW; Oyen, WJ; Stearne, LE; van der Meer, JW; Verbrugh, HA1

Other Studies

4 other study(ies) available for trovafloxacin and E coli Infections

ArticleYear
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
    Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:10

    Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Escherichia coli Infections; Female; Fluoroquinolones; Male; Mice; Naphthyridines; Pneumococcal Infections

1995
In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:3

    Topics: Abdominal Abscess; Animals; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Male; Microbial Sensitivity Tests; Naphthyridines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha

1997
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2000, Volume: 6, Issue:12

    Topics: Albumins; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Globulins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suppuration

2000
In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:5

    Topics: Abscess; Animals; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Blood Proteins; Disease Models, Animal; Enterococcus faecium; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Immunoglobulin G; Mice; Mice, Inbred BALB C; Naphthyridines; Treatment Outcome; Vancomycin Resistance

2001